Background: Neuropsychiatric symptoms, also known as behavioral and psychological symptoms of dementia (BPSD), affect the majority of patients with dementia, and result in a greater cognitive and functional impairment.
Objective: To investigate associations between BPSD and amyloid cerebral deposition as measured by 18F-Florbetapir-PET quantitative uptake in elderly subjects with and without cognitive impairment.
Methods: Participants with cognitive impairment [mild cognitive impairment (MCI) or Alzheimer's disease (AD)] and healthy controls (HC) from the ADNI cohort (Alzheimer Disease Neuroimaging Initiative) who underwent an 18F-florbetapir PET scan between May 2010 and March 2014 were included. Clinical assessments included the Clinical Dementia Rating, the Mini-Mental State Examination (MMSE), and the Neuropsychiatric Inventory. Freesurfer software was used to extract PET counts based on T1-based structural ROI (frontal, cingulate, parietal, and temporal). Spearman's partial correlation scores between BPSD severity and regional amyloid uptake were calculated.
Results: Data for 657 participants [age = 72.6 (7.19); MMSE = 27.4 (2.67)] were analyzed, including 230 HC [age = 73.1 (6.02); MMSE = 29 (1.21)], 308 MCI [age = 71.5 (7.44); MMSE = 28.0 (1.75)], and 119 AD subjects [age = 74.7 (8.05); MMSE = 23.1 (2.08)]. Considering all diagnostic groups together, positive significant correlations were found between anxiety and 18F-florbetapir uptake in the frontal (r = 0.102; p = 0.009), cingulate (r = 0.083; p = 0.034), and global cerebral uptake (r = 0.099; p = 0.011); between irritability and frontal (r = 0.089; p = 0.023), cingulate (r = 0.085; p = 0.030), parietal (r = 0.087; p = 0.025), and global cerebral uptake (r = 0.093; p = 0.017); in the MCI subgroup, between anxiety and frontal (r = 0.126; p = 0.03) and global uptake (r = 0.14; p = 0.013); in the AD subgroup, between irritability and parietal uptake (r = 0.201; p = 0.03).
Conclusion: Anxiety and irritability are associated with greater amyloid deposition in the neurodegenerative process leading to AD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3233/JAD-150181 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Basic Science and Pathogenesis.
Alzheimers Dement
December 2024
Duke University School of Medicine, Durham, NC, USA.
Background: Patients with Alzheimer's Disease (AD) frequently manifest comorbid neuropsychiatric symptoms (NPS) with depression and anxiety being most prevalent. Previously we identified shared genetic risk loci between AD and major depressive disorder (MDD). In another study, we constructed a polygenic risk score (PRS) based on MDD-GWAS data and demonstrated its performance in predicting depression onset in LOAD patients.
View Article and Find Full Text PDFBasic Science and Pathogenesis.
Alzheimers Dement
December 2024
Columbia University, New York, NY, USA.
Background: As high as 50% of Alzheimer's disease (AD) patients experience "sundowning", which refers to an increased severity of neuropsychiatric symptoms (NPS), including agitation, confusion, and anxiety, selectively in the evening. Although sundowning significantly influences the decision to institutionalize patients, few preclinical models of this phenomenon exist and the underlying neural mechanisms are unknown. Here, we establish a model of sundowning by phenotyping the sleep-wake cycle and anxiety and exploratory behavior at different times of day in an AD mouse model.
View Article and Find Full Text PDFBasic Science and Pathogenesis.
Alzheimers Dement
December 2024
Laboratory of Neuroscience (LIM27), Departamento e Instituto de Psiquiatria, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, São Paulo, São Paulo, Brazil.
Background: Nearly all individuals with Alzheimer's disease (AD) develop neuropsychiatric symptoms (NPS). Lithium is a mood-stabilizer and is efficient in reducing disruptive behaviors in bipolar-disorder; this characteristic could be an opportunity to investigate the use of lithium in treating behavioral changes in AD.
Method: We tested lithium carbonate treatment in 3xTg-AD and age-matched Wild-type male mice (CEUA/PROCESS: 1605/2020; 4127240122).
Basic Science and Pathogenesis.
Alzheimers Dement
December 2024
The Clinical Hospital of Chengdu Brain Science Institute, MOE Key Lab for Neuroinformation, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, China.
Background: To study the morphological characteristics of the thalamus in cognitively normal people with apolipoprotein E epsilon 4 (APOE ε4), and to explore whether it is affected by neuropsychiatric symptoms in patients aged between 60 and 70 years, and to provide evidence for the early brain structural changes in Alzheimer's disease.
Method: Clinical assessment, neuropsychological assessment, blood text and MRI examination were performed in 101 cognitively normal elderly patients in a tertiary psychiatric memory clinic in Chengdu. The cognitive function and thalamic volume of APOE ε4 carriers (n = 30) and APOE ε4 non-carriers (n = 71) were compared using an independent sample T-test.
Basic Science and Pathogenesis.
Alzheimers Dement
December 2024
G. H. Sergievsky Center, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.
Background: Neuropsychiatric Symptoms (NPS) (e.g., aggression, psychosis, anxiety, apathy, depression, agitation, sleep disturbances, repetitive behaviors) occur in 85% of AD patients, and are associated with accelerated decline, out-of-home placement, increased costs, and greatly increased suffering of patients and families.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!